Effect of antiviral therapy on the survival and incidence of major complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension

Table 2 Univariate and multivariate analysis of the overall survival of patients with HBV-related cirrhosis undergoing splenectomy for hypersplenism and portal hypertension

	No. of patients	Overall Survival (%)	3 year	5 year	Univariate analysis	Multivariate analysis	P
		1 year			P	HR (95% CI)
Antiviral therapy					0.230	2.272(0.952–5.424)	0.064
Yes	28	100.0	100.0	100.0
No	29	100.0	90.5	67.9
Gender					0.466	0.359(0.097–1.329)	0.125
Men	44	100.0	95.2	81.4
Women	13	100.0	88.9	88.9
Age (years)					0.782	1.513(0.701–3.263)	0.291
≤ 40	26	100.0	94.1	94.1
> 40	31	100.0	94.4	62.9
Child–Pugh grade					0.336	1.061(0.482–2.338)	0.883
A	19	100.0	100.0	100.0
B and C	38	100.0	91.3	76.1
WBC (×10⁹/L)					0.592	0.352(0.109–1.142)	0.082
≥ 3	20	100.0	90.0	45.0
< 3	37	100.0	96.0	96.0
Platelet (×10⁹/L)					0.289	3.951(0.901–17.333)	0.069
≥ 50	13	100.0	85.7	42.9
< 50	44	100.0	96.4	96.4
ALT (IU/L)					0.814	0.990(0.289–3.388)	0.987
< 40	28	100.0	94.7	94.7
≥ 40	29	100.0	93.3	74.6
AST (IU/L)					0.997	0.273(0.082–0.907)	0.034
< 40	27	100.0	94.1	94.1
≥ 40	30	100.0	94.4	78.6
Serum bilirubin (μmol/L)					0.595	1.137(0.262–4.935)	0.864
< 40	49	100.0	93.75	82.0
≥ 40	8	100.0	100.0	100.0
Serum albumin (g/L)					0.397	2.603(0.885–7.657)	0.082
≥ 32	41	100.0	92.5	79.3
< 32	16	100.0	100.0	100.0
INR					0.716	0.212(0.072–0.630)	0.005
< 1.2	25	100.0	92.8	92.8
≥ 1.2	32	100.0	95.2	81.6
HBeAg					0.861	4.823(1.772–13.129)	0.002
Positive	22	100.0	94.1	94.1
Negative	35	100.0	94.4	75.5
HBV DNA (IU/ml)					0.964	0.919(0.349–2.421)	0.864
< 10⁴	26	100.0	100.0	75.0
≥ 10⁴	31	100.0	95.2	95.2

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; INR, international normalized ratio; IU, international unit; WBC, white blood cell; HR, hazard ratio; 95% CI, 95% confidence interval.

ISSN: 1743-422X